MPN Research News
- New grant opportunity for myelofibrosis (January 2012)
- A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2 (January 2012)
- Seeking patients for familial MPN study (January 2012)
- MPN Science Report from ASH (January 2012)
- New study on myelofibrosis by Ayalew Tefferi (January 2012)
- Update on YM BioSciences MF drug (December 2011)
- Eli Lily announces data from Phase I of JAK2 trial (December 2011)
- FDA Approves Incyte's Jakafi(TM) (ruxolitinib) for Patients with Myelofibrosis (November 2011)
- SBio to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (October 2011)
- YM BioSciences Initiates Phase II BID Trial with CYT387 in Myelofibrosis (September 2011)
- Interferon and PV cells (August 2011)
- Blood consult: resistant and progressive essential thrombocythemia (July 2011)
- The dominant negative isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from PV patients (July 2011)
- Incyte nears finish line for the first FDA approved treatment for myelofibrosis (June 2011)
- MPN research advances MPN drugs to market: a report from ASCO (June 2011)
- Recombinant interferon alpha may retard progression of early primary myelofibrosis: a preliminary report (June 2011)
- The renassaince of interferon therapy for the treatment of myeloid malignancies (May 2011)
- The MPN symptom assessment form (May 2011)
- Questions from Pennsylvania PV cluster (May 2011)
- How one doctor treats myelofibrosis (April 2011)
- Patients push researchers to share data (March 2011)
- European journal reviews current JAK inhibitors (April 2011)
- From Blood: How some doctors treat essential thrombocythemia (March 2011)
- 2011 MPN Research Foundation grant recipients (February 2011)
- MD Anderson newsletter reports on developments in MPN (February 2011)
- Geron enrolls first ET patient (January 2011)
- Report from ASH (December 2011)
- Incyte study meets goals for Myelofibrosis patients (December 2010)
- MPD videos released by ASCO (December 2010)
- Doctors report on promising JAK inhibitors at ASH (December 2010)
- MPD Chat compiles list of MPD-relevant abstracts (December 2010)
- Thrombosis risk rises in women with myeloproliferative disorders (December 2010)
- SBio reports positive data on JAK2 Inhibitor trial for MF patients (December 2010)
- Incyte reports positive results in ET and PV trials of JAK Inhibitor (December 2010)
- Doctors report on promissing JAK inhibitors at ASH (December 2010)
- SBio granted orphan drug designation for Myelofibrosis drug (October 2010)
- Report from India on prevalence of JAK2 among Indian MPD patients (October 2010)
- New model for predicting risk of blood clot in cancer patients (October 2010)
- Incyte approved by FDA for special PV protocol (September 2010)
- Sanofi-Aventis purchases TargeGen, developer of drugs for Myeloproliferative Disorders (September 2010)
- Incyte to test drug in PV patients (August 2010)
- MPD Foundation announces call for proposals (May 2010)
- Report on JAK2 community screening in PA (May 2010)
- YM Biosciences moves forward with JAK2 Inhibitor (March 2010)
- Study tests new prognostic tool for myelofibrosis (March 2010)
- Major grant awarded for leukemia and myelofibrosis (February 2010)
- Survival study on Myelofibrosis patients published by Dr. Tefferi (PDF)
- News from ASH (December 2009)
- MPD Foundation attends ASH's annual meeting (December 2009)
- Survival data on MF patients (December 2009)
- CeMM Identifies Inherited Susceptibility for Blood Malignancy (March 2009)
- MPD Foundation Announces 2009 Grant Award Recipients (February 2009)
- Abstract for the Phase 1 clinical trials of XL019, a JAK2 Inhibitor, to be discussed at ASH's annual meeting (December 2008)
- Cytopia appoints Dr. Ayalew Tefferi study chairman for JAK2 clinical trial (July 2008)
- The MPD Foundation announces call for proposals for New Investigator and Research Alliance grant programs (July 2008)
- Abstract: Prevalence of polycythemia vera and essential thrombocythemia (May 2008)
- Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors (April 2008)
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera (April 2008)
- New Cancer Discovery, Hormone to Blame
- Top Scientists to Receive Prestigious Awards From the American Society of Hematology
- TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations (PDF)
- Gene Mutation Predicts Outcome in Blood Disorder
- LLS's Prestigious Specialized Center of Research Program Hits $159 Million Mark
- University of Utah to Investigate Blood Disorders
- Discovery of a new mutation in JAK2V617F negative myelofibrosis patients
- Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia (April 2006)
- UIC Receives $20 Million NCI Grant to Research Blood Disorders
- April 19, 2006 UIC joins forces with Harvard, Mayo Clinic to battle bone marrow disorders
- Medical Research News Article Discusses the MPD Research Alliance
- Interview with Dr. Gilliland, PhD, MD
- MPD Gene Discovery!
- Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg Sweden during 1983-99 (August 2004)
- 2004 Grant Awards
- Agent Orange and Cancer: An Overview for Physicians (2003)
- Familial polycythemia vera: results from the Swedish Family-Cancer Database (August 2001)
- Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythemia vera and idiopathic myelofibrosis (March 2001)
- The Italian registry of myelofibrosis is one year old (November 2000)
- Incidence of chronic myeloproliferative disorders in the city of Goteborg, Sweden 1983-1992 (May 1999)
- Population-based incidence and survival in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County Study, 1976-1995 (May 1999)
- Age and sex distributions of hematological malignancies in the U.K. (1997)
- Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989 (October 1994)
- Incidence of polycythemia vera in a defined population (January 1992)
- Study Links ESAs to Higher Leukemia Risk for Some
- Incyte and Novartis announce collaboration on JAK2 Inhibitor currently in Phase III clinical trial
- Incyte Reaches Agreement With FDA on Myelofibrosis Drug
- Biotech industry steadily working on JAK2 Inhibitors
- From ASH: Incyte's JAK2 Inhibitor Demonstrates Benefits in Myelofibrosis Patients
- Pegylated Interferon Alfa-2a yields high response from ET and PV patients
- PV and ET Patients Needed for New Clinical Trial
- Incyte's JAK2 Inhibitor Demonstrates Clinical Benefit for Myelofibrosis Patients in Ongoing Clinical Trial
- UCSD, TargeGen team-up on blood disease treatment
- Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders - Clinical Study to Commence Late This Year
- Incyte Reports Success in Multiple Clinical Programs; Expands JAK Inhibitor Program
- TargeGen Announces Initiation of JAK2 Inhibitor TG101348 Trial for Myeloproliferative Disorder Patients
- JAK2 Inhibitor Shows Potent Activity in Cells from MPD Patients
- Exelixis Reports Data from Ongoing Phase 1 Study of XL019 to Treat Myelofibrosis
- Exelixis Winning Phase I Race
- Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
- Novartis drug wins expanded FDA approval
